RCKT vs. VRNA, BHVN, CRNX, ACLX, APLS, PTCT, RNA, IMVT, RYTM, and ACAD
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Verona Pharma (VRNA), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), Arcellx (ACLX), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs.
Rocket Pharmaceuticals (NASDAQ:RCKT) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
Rocket Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
Verona Pharma has higher revenue and earnings than Rocket Pharmaceuticals. Verona Pharma is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals' return on equity of -62.62% beat Verona Pharma's return on equity.
Rocket Pharmaceuticals presently has a consensus target price of $47.27, suggesting a potential upside of 358.51%. Verona Pharma has a consensus target price of $50.57, suggesting a potential downside of 2.54%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Verona Pharma.
Rocket Pharmaceuticals received 64 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.74% of users gave Verona Pharma an outperform vote while only 73.22% of users gave Rocket Pharmaceuticals an outperform vote.
In the previous week, Verona Pharma had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 6 mentions for Verona Pharma and 3 mentions for Rocket Pharmaceuticals. Verona Pharma's average media sentiment score of 0.47 beat Rocket Pharmaceuticals' score of 0.23 indicating that Verona Pharma is being referred to more favorably in the news media.
98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 28.5% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Verona Pharma beats Rocket Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 1/20/2025 by MarketBeat.com Staff
Free RCKT Stock Alerts